FDA Approves Inluriyo (imlunestrant) in Combination with Verzenio (abemaciclib) for Adults with ER+, HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer
NDA FilingapprovedInluriyoVerzenioPositive
AI Analysis
Summary
Eli Lilly received FDA approval for Inluriyo (imlunestrant) in combination with Verzenio (abemaciclib) to treat adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer. This represents a significant regulatory milestone for the company's oncology portfolio.
Outcome Details
FDA granted full approval to Inluriyo (imlunestrant) in combination with Verzenio (abemaciclib)
Importance:9/10
Sentiment:
0.95
FDA approvaloncologybreast cancerestrogen receptor positivecombination therapy
Related Companies
Read the original article
Published by Drugs.com New Drug Approvals on September 18, 2026 9:09 PM